We thank Lin for valuable comments on our article.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Archives of Physical Medicine and Rehabilitation
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Published online: January 20, 2015
© 2015 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- Predicting the Response to Botulinum Toxin Treatment in Children With Cerebral PalsyArchives of Physical Medicine and RehabilitationVol. 96Issue 4
- PreviewIt is interesting to read the article by Bar-On et al.1 They compared the responsiveness of clinical and instrumented spasticity assessment for the effects of botulinum toxin type A injection in children with cerebral palsy. However, in the entire article, they used the abbreviated term BTX rather than the distinct trade name for botulinum toxin to denote the medication they injected. I strongly recommend that the authors need to clarify the formulation of botulinum toxin to avoid misunderstanding.